03 | MD Anderson Cancer Center

Single agent umbralisib effective for relapsed slow-growing lymphoma

April 01, 2019

A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.

MZL is a low-grade non-Hodgkin lymphoma that accounts...

New potential therapeutic target for pancreatic cancer discovered

BY Rolaynne Kimmons

March 27, 2019

Cancer cells demand enormous amounts of molecular “food” to survive and grow, and a study published March 27 online in Nature by researchers...

Study may explain why immunotherapy not effective for some patients with metastatic melanoma and kidney cancer

BY Rolaynne Kimmons

March 25, 2019

White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint...

Study points to new strategy for boosting immunotherapy effectiveness in advanced colorectal cancer

March 21, 2019

Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond to immune checkpoint blockade (ICB) therapy.

Findings from the study, published in the March 21 online issue of Cancer Cell, shows how KRAS, a key mutation in colorectal cancer, promotes metastasis by controlling the immune-suppressive...